226 related articles for article (PubMed ID: 29601137)
1. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
Yamaguchi M; Suzuki R; Kim SJ; Ko YH; Oguchi M; Asano N; Miyazaki K; Terui Y; Kubota N; Maeda T; Kobayashi Y; Amaki J; Soejima T; Saito B; Shimoda E; Fukuhara N; Tsukamoto N; Shimada K; Choi I; Utsumi T; Ejima Y; Kim WS; Katayama N
Cancer Sci; 2018 Jun; 109(6):2056-2062. PubMed ID: 29601137
[TBL] [Abstract][Full Text] [Related]
2. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of NK/T-cell lymphoma: current situations and prospectives].
Yamaguchi M
Rinsho Ketsueki; 2018; 59(5):588-593. PubMed ID: 29877250
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
6. Current and future management of NK/T-cell lymphoma based on clinical trials.
Yamaguchi M
Int J Hematol; 2012 Nov; 96(5):562-71. PubMed ID: 23073619
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
Yamaguchi M; Tobinai K; Oguchi M; Ishizuka N; Kobayashi Y; Isobe Y; Ishizawa K; Maseki N; Itoh K; Usui N; Wasada I; Kinoshita T; Ohshima K; Matsuno Y; Terauchi T; Nawano S; Ishikura S; Kagami Y; Hotta T; Oshimi K
J Clin Oncol; 2009 Nov; 27(33):5594-600. PubMed ID: 19805668
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
[TBL] [Abstract][Full Text] [Related]
9. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
Kwong YL; Kim SJ; Tse E; Oh SY; Kwak JY; Eom HS; Do YR; Mun YC; Lee SR; Shin HJ; Suh C; Chuang SS; Lee YS; Lim ST; Izutsu K; Suzuki R; Relander T; d'Amore F; Schmitz N; Jaccard A; Kim WS
Ann Oncol; 2018 Jan; 29(1):256-263. PubMed ID: 29077846
[TBL] [Abstract][Full Text] [Related]
10. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
Makita S; Tobinai K
Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
[TBL] [Abstract][Full Text] [Related]
12. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yamaguchi M; Suzuki R; Oguchi M
Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma.
Tsai HJ; Lin SF; Chen CC; Chen TY; Su WC; Hwang WL; Lin JC; Chiou TJ; Kao WY; Chiu CF; Chang YF; Chang JS; Chang MC; Su IJ
Eur J Haematol; 2015 Feb; 94(2):130-7. PubMed ID: 24957163
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
[TBL] [Abstract][Full Text] [Related]
16. Nomograms to predict progression of disease within 24 months in patients with localized natural killer/T-cell lymphoma.
Li N; Jiang M; Wu WC; Zou LQ
Future Oncol; 2022 Oct; 18(32):3573-3583. PubMed ID: 36507722
[No Abstract] [Full Text] [Related]
17. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
18. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
Kim SJ; Yoon DH; Jaccard A; Chng WJ; Lim ST; Hong H; Park Y; Chang KM; Maeda Y; Ishida F; Shin DY; Kim JS; Jeong SH; Yang DH; Jo JC; Lee GW; Choi CW; Lee WS; Chen TY; Kim K; Jung SH; Murayama T; Oki Y; Advani R; d'Amore F; Schmitz N; Suh C; Suzuki R; Kwong YL; Lin TY; Kim WS
Lancet Oncol; 2016 Mar; 17(3):389-400. PubMed ID: 26873565
[TBL] [Abstract][Full Text] [Related]
19. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma.
Suzuki R
Semin Hematol; 2014 Jan; 51(1):42-51. PubMed ID: 24468315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]